Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

BACKGROUND: Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jacob K., Zobel, Emilie H., von Scholten, Bernt J., Rotbain Curovic, Viktor, Hansen, Tine W., Rossing, Peter, Kjaer, Andreas, Ripa, Rasmus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669791/
https://www.ncbi.nlm.nih.gov/pubmed/34917038
http://dx.doi.org/10.3389/fendo.2021.790405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669791/
https://www.ncbi.nlm.nih.gov/pubmed/34917038
http://dx.doi.org/10.3389/fendo.2021.790405

Ejemplares similares